Companion Medical launched today Insights by InPen, a diabetes management system that aggregates and analyzes data from Companion’s connected insulin injection pen.
The company’s Insights by InPen system provides users with their average glucose, average total daily insulin dose, dose calculator usage, missed doses and more, according to Companion Medical.
The system is available in the U.S. by prescription only.
“Complete and reliable data are vital for people with diabetes and their healthcare providers,” CEO Sean Saint said in prepared remarks. “The InPen system empowers MDI users with meaningful, actionable and accessible data that can be sent from their phone directly to their physician. Using Insights by InPen, healthcare providers can optimize treatment for MDI users, just as they do for insulin pump users.”
Companion Medical’s InPen device is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin.
